anti ca125  (R&D Systems)

Journal: The Journal of Molecular Diagnostics : JMD

Article Title: Improving Specificity for Ovarian Cancer Screening Using a Novel Extracellular Vesicle–Based Blood Test

doi: 10.1016/j.jmoldx.2024.09.001

Figure Lengend Snippet: OC Test and CA125 enzyme-linked immunosorbent assay performance in healthy controls and in ovarian cancers. A and C: Training study EDTA plasma samples are shown. B and D : The verification study serum samples are shown. The cutoff set between healthy controls and OC cases is shown as a red dotted line in each graph. HGSC, high-grade serous carcinoma; LGSC, low-grade serous carcinoma.

Article Snippet: The Human CA125/MUC16 Quantikine enzyme-linked immunosorbent assay (ELISA) kit (catalog number DCA 125; R&D Systems, Minneapolis, MN) was used to measure the CA125 level in all EDTA plasma and serum samples.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: The Journal of Molecular Diagnostics : JMD

Article Title: Improving Specificity for Ovarian Cancer Screening Using a Novel Extracellular Vesicle–Based Blood Test

doi: 10.1016/j.jmoldx.2024.09.001

Figure Lengend Snippet: OC Test and CA125 enzyme-linked immunosorbent assay performance in benign ovarian conditions. A and C: Training study EDTA plasma samples are shown. B and D: The verification study serum samples are shown. The cutoff set between healthy controls and OC cases is shown as a red dotted line in each graph.

Article Snippet: The Human CA125/MUC16 Quantikine enzyme-linked immunosorbent assay (ELISA) kit (catalog number DCA 125; R&D Systems, Minneapolis, MN) was used to measure the CA125 level in all EDTA plasma and serum samples.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: The Journal of Molecular Diagnostics : JMD

Article Title: Improving Specificity for Ovarian Cancer Screening Using a Novel Extracellular Vesicle–Based Blood Test

doi: 10.1016/j.jmoldx.2024.09.001

Figure Lengend Snippet: OC Test and CA125 enzyme-linked immunosorbent assay performance in nonovarian cancers and inflammatory conditions. A and C: Nonovarian (off-target cancer) samples are shown. B and D: The inflammatory condition samples are shown. The cutoff set between healthy controls and OC cases is shown as a red dotted line in each graph.

Article Snippet: The Human CA125/MUC16 Quantikine enzyme-linked immunosorbent assay (ELISA) kit (catalog number DCA 125; R&D Systems, Minneapolis, MN) was used to measure the CA125 level in all EDTA plasma and serum samples.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Nature biotechnology

Article Title: Design of a mucin-selective protease for targeted degradation of cancer-associated mucins

doi: 10.1038/s41587-023-01840-6

Figure Lengend Snippet: a, Digestion of recombinant human MUC16 (rhMUC16) with eStcE alone or nanobody-eStcE conjugates. b, rhMUC16 in-gel digest depicting degradation of eStcE-αHER2 conjugate after long-term storage at 4 °C. c, Representative flow plots showing cell surface binding of nanobody alone and eStcE-αHER2 on MCF10AHER2 cells measured by anti-His staining. d, Cell surface binding curves derived from mean fluorescence intensity from (c) (n = 3 biologically independent replicates). e, Kd values derived from (d). f, Representative flow plots showing cell surface binding of αHER2-eStcE on MCF10A±MUC1, ±HER2 cells measured by anti-His staining. Flow plot of αHER2-eStcE on MCF10AHER2 is shown in (c). g, Kd values derived from mean fluorescence intensity from (f) and Fig. 3c (n = 3 biologically independent replicates). The MCF10AHER2 bar depicts the same data as the αHER2-eStcE bar in (e). Data are mean ± s.d. P-values were determined using Tukey-corrected one-way ANOVA. *p < 0.05, **p < 0.005, ***p < 0.0005.

Article Snippet: For recombinant human MUC16 digestion experiments, recombinant MUC16 (R&D Systems) was left unlabeled but was otherwise treated as described above.

Techniques: Recombinant, Binding Assay, Staining, Derivative Assay, Fluorescence

Journal: Nature biotechnology

Article Title: Design of a mucin-selective protease for targeted degradation of cancer-associated mucins

doi: 10.1038/s41587-023-01840-6

Figure Lengend Snippet: a-b, 4T07MUC1 cells (a) and OVCAR-3 cells (b) were treated with 50 nM StcE for 2 hours, washed 1x with 2 mM EDTA followed by 5x with DPBS, then cultured for the indicated times. Cells were then lysed and subjected to Western blotting for MUC1 (a) and MUC16 (b). Mucin bands are denoted by black arrows. c, Bioluminescent imaging of animals described in Fig. 4e. d, Total flux measurements quantified from (c). e, Plot depicting mouse masses of animals described in Fig. 4e. f-g, H&E staining of lungs from PBS-treated (f) or αHER2-eStcE treated (g) animals (n = 7 animals per group, 2 slides per animal). Percent area of lung metastases is quantified in Fig. 4g. h, Quantification of images from Supplementary Fig. 6 using the IHC profiler plugin in ImageJ. Percent positive corresponds to positive DAB staining in the cytosol. i, Quantification of images from Supplementary Fig. 7 using the IHC profiler plugin in ImageJ. Percent positive corresponds to positive DAB staining in the cytosol. j, Quantification of images from Supplementary Fig. 8 using the IHC profiler plugin in ImageJ. Percent positive corresponds to positive DAB staining in the nucleus. k, Treatment regimen for BALB/c mice injected intravenously (I.V.) via tail vein with 4T07MUC1, HER2 cells. Doxycycline was included in the chow for the duration of the experiment to maintain MUC1 ectodomain expression. αHER2-eStcE at 10 mg/kg or an equimolar quantity of αHER2-eStcEE447D or αGFP-eStcE were injected I.V. every other day starting on day 0 (n = 9 animals per group). l, Total flux of the indicated days normalized to the total flux on day 0 for each mouse quantified from Supplementary Fig. 10. Data are mean ± s.e.m. P-values were determined using two-tailed Mann-Whitney test (d-e), two-tailed unpaired t-test (h-j), or Tukey-corrected one-way ANOVA (l). *p < 0.05, **p < 0.005, ***p < 0.0005.

Article Snippet: For recombinant human MUC16 digestion experiments, recombinant MUC16 (R&D Systems) was left unlabeled but was otherwise treated as described above.

Techniques: Cell Culture, Western Blot, Imaging, Staining, Injection, Expressing, Two Tailed Test, MANN-WHITNEY